Exploring the Economic and Social Dimension of COVID-19 Vaccination Using a Budget Impact Analysis.

M. Traunfellner, F. Meyer, E. Walter

Value & Outcomes Spotlight. 2022

siehe Link (Seite 18-21)

Impact of metabolic surgery on long-term health outcome: a cost-effectiveness approach.

E. Walter, F. B. Langer, P. Beckerhinn, F. Hoffer, G. Prager

Surg Obes Relat Dis. 2022

siehe Link

Cost-effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients.

E. Walter, M. Voit, G. Eichhober

Expert Rev Pharmacoecon Outcomes Res. 2021

siehe Link

Health-related quality of life, work productivity and costs related to patients with inflammatory bowel disease in Austria.

E. Walter, S.C. Hausberger, E. Groß, U. Siebert

J Med Econ. 2020 

siehe Link

Economic impact of industry-sponsored clinical trials of pharmaceutical products in Austria.

E. Walter, G. Eihhober, M. Voit, C. Baumgartner, A. Celedin, C. Holzhauser, B. Mraz, C. Ornauer, J. Pleiner-Duxneuner, B. Ponner, I. Presch, G. Pum, H. Tieben, G. Weingartmann, D. Baltic, W. Bonitz, S.T. Kaehler.
J Med Econ. 2020

siehe Link

Cost-Effectiveness Analysis of Landiolol, an Ultrashort-Acting Beta-Blocker, for Prevention of Postoperative Atrial Fibrillation for the Germany Health Care System.

E. Walter, M. Heringlake
J Cardiothorac Vasc Anesth. 2019 Nov 9.

siehe Link

Approaches to Capturing Value in Oncology.

E. Walter
In: E. Walter (eds) Regulatory and Economic Aspects in Oncology. Recent Results in Cancer Research, vol 213. Springer, Cham

siehe Link

Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria.

E. Walter, T. Berger, B. Bajer-Kornek, F. Deisenhammer
J Med Econ. 2019 Mar; 22(3): 226-237.

siehe Link

Cost-utility analysis of fracture risk assessment using microRNAs compared with standard tools and no monitoring in the Austrian female population.

E. Walter, H. Dellago, J. Grillari, H. P.  Dimai

Hackl M. Bone. Mar 2018; 108:44-54

siehe Link

Congenital toxoplasmosis in Austria: Prenatal screening for prevention is cost-saving.

A. R. Prusa, D.C. Kasper, L. Sawers, E. Walter, M. Hayde, E. Stillwagon
PLoS Negl Trop Dis., Jul 2017

siehe Link

Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany

E. Walter, P. Odin
J Med Econ. 2015 Feb; 18(2):155-65.

siehe Link

Socio-economic aspects of the testing for antibodies in MS-Patients under Interferon Therapy in Austria: A cost of Illness Study

E. Walter, F. Deisenhammer
Multiple Sclerosis and Related Disorders. 2014, Volume 3, Issue 6, Pages 670-677.

siehe Link

Kosteneffektivität der primärprofilatischen Gabe von Pegfilgrastim vs. Filgrastim bei Brustkrebspatienten in Österreich

E. Walter 
Recht der Medizin Beilage Gesundheit und Ökonomie, Dezember 2013

Cost Efectividad del Tratamiento de la Anemia inducida por quimioteerapia con agentes estimuladores dela Eritropoyesis

C. A. Rodríguez, A. Alegre, J. Cassinello, L. Guiérrez, C. Crespo, A. Villacampa, E. Walter
PharmaEconomics Spanish Resarch Articles, August 2013

siehe Link